Improving Beta Cell Function in Mexican American Women With Prediabetes

This study will examine the benefits of weight loss alone or in combination with a GLP1
receptor agonist, liraglutide, on beta cell function in young adult Mexican American (MA)
women with prediabetes. The Investigators have chosen to focus on MA women because MA women
are at very high risk for progression to diabetes and have not traditionally been involved in
weight management studies since they are thought to be difficult to recruit and retain in
such programs. However, investigators have had particular success in working with young MA
women using specifically developed ethnic and gender conscious programs. Because weight loss
does not prevent all progression to diabetes, some participants will receive the diabetes
medication, liraglutide, which has been shown to stabilize beta cell function. The study will
also interrogate for polymorphisms of known T2DM genes to correlate with beta cell response
to weight loss and liraglutide treatment. Additionally, this investigation targets serious
health disparities in metabolic disease in a highly vulnerable, rapidly growing population,
testing novel gender and culturally focused intervention strategies and identifying genetic
biomarkers of response to a pharmacologic intervention that targets the pancreatic ßcell.

These results will help to a) understand mechanisms of disease, b) personalize treatment
through identification of a high risk group that may be amenable to specific therapy, and c)
ultimately, sets the stage for an intervention trial to prevent diabetes, a major chronic and
costly disease, in Mexican Americans.